198 related articles for article (PubMed ID: 38114573)
1. Novel HER2-targeted therapy to overcome trastuzumab resistance in HER2-amplified gastric cancer.
Park J; Kang SK; Kwon WS; Jeong I; Kim TS; Yu SY; Cho SW; Chung HC; Rha SY
Sci Rep; 2023 Dec; 13(1):22648. PubMed ID: 38114573
[TBL] [Abstract][Full Text] [Related]
2. The Future of HER2-Targeted Treatment for Osteosarcoma: Lessons from the Negative Trastuzumab Deruxtecan Results.
Nakano K
Int J Mol Sci; 2023 Nov; 24(23):. PubMed ID: 38069146
[TBL] [Abstract][Full Text] [Related]
3. Discovery and development of trastuzumab deruxtecan and safety management for patients with HER2-positive gastric cancer.
Shitara K; Baba E; Fujitani K; Oki E; Fujii S; Yamaguchi K
Gastric Cancer; 2021 Jul; 24(4):780-789. PubMed ID: 33997928
[TBL] [Abstract][Full Text] [Related]
4. Lapatinib sensitivities of two novel trastuzumab-resistant HER2 gene-amplified gastric cancer cell lines.
Oshima Y; Tanaka H; Murakami H; Ito Y; Furuya T; Kondo E; Kodera Y; Nakanishi H
Gastric Cancer; 2014; 17(3):450-62. PubMed ID: 23948998
[TBL] [Abstract][Full Text] [Related]
5. The effects of T-DXd on the expression of HLA class I and chemokines CXCL9/10/11 in HER2-overexpressing gastric cancer cells.
Nakajima S; Mimura K; Matsumoto T; Thar Min AK; Ito M; Nakano H; Neupane P; Kanke Y; Okayama H; Saito M; Momma T; Watanabe Y; Hanayama H; Hayase S; Saze Z; Kono K
Sci Rep; 2021 Aug; 11(1):16891. PubMed ID: 34413454
[TBL] [Abstract][Full Text] [Related]
6. In Vivo and In Vitro Efficacy of Trastuzumab Deruxtecan in Uterine Serous Carcinoma.
Mutlu L; Manavella DD; Bellone S; McNamara B; Harold JA; Mauricio D; Siegel ER; Buza N; Hui P; Hartwich TMP; Yang-Hartwich Y; Demirkiran C; Verzosa MSZ; Altwerger G; Ratner ES; Huang GS; Clark M; Andikyan V; Azodi M; Dottino PR; Schwartz PE; Santin AD
Mol Cancer Ther; 2023 Dec; 22(12):1404-1412. PubMed ID: 37676984
[TBL] [Abstract][Full Text] [Related]
7. Trastuzumab deruxtecan for the treatment of HER2-positive gastric cancer.
Mishima S; Shitara K
Expert Opin Biol Ther; 2021 Jul; 21(7):825-830. PubMed ID: 33798395
[No Abstract] [Full Text] [Related]
8. The evolving therapeutic landscape of trastuzumab-drug conjugates: Future perspectives beyond HER2-positive breast cancer.
von Arx C; De Placido P; Caltavituro A; Di Rienzo R; Buonaiuto R; De Laurentiis M; Arpino G; Puglisi F; Giuliano M; Del Mastro L
Cancer Treat Rev; 2023 Feb; 113():102500. PubMed ID: 36587473
[TBL] [Abstract][Full Text] [Related]
9. Adavosertib Enhances Antitumor Activity of Trastuzumab Deruxtecan in HER2-Expressing Cancers.
DiPeri TP; Evans KW; Raso MG; Zhao M; Rizvi YQ; Zheng X; Wang B; Kirby BP; Kong K; Kahle M; Yap TA; Dumbrava EE; Ajani JA; Fu S; Keyomarsi K; Meric-Bernstam F
Clin Cancer Res; 2023 Nov; 29(21):4385-4398. PubMed ID: 37279095
[TBL] [Abstract][Full Text] [Related]
10. Exploring DESTINY: the Past, Present, and Future of Trastuzumab Deruxtecan.
Ali A; Graff SL
Curr Oncol Rep; 2024 Jan; 26(1):1-9. PubMed ID: 38091201
[TBL] [Abstract][Full Text] [Related]
11. Trastuzumab deruxtecan for the treatment of HER2-positive advanced gastric cancer: a clinical perspective.
Aoki M; Iwasa S; Boku N
Gastric Cancer; 2021 May; 24(3):567-576. PubMed ID: 33646464
[TBL] [Abstract][Full Text] [Related]
12. Resistance Mechanism against Trastuzumab in HER2-Positive Cancer Cells and Its Negation by Src Inhibition.
Jin MH; Nam AR; Park JE; Bang JH; Bang YJ; Oh DY
Mol Cancer Ther; 2017 Jun; 16(6):1145-1154. PubMed ID: 28223426
[TBL] [Abstract][Full Text] [Related]
13. Trastuzumab Deruxtecan: Changing the Destiny of HER2 Expressing Solid Tumors.
Indini A; Rijavec E; Grossi F
Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33946310
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of HSP90 with AUY922 induces synergy in HER2-amplified trastuzumab-resistant breast and gastric cancer.
Wainberg ZA; Anghel A; Rogers AM; Desai AJ; Kalous O; Conklin D; Ayala R; O'Brien NA; Quadt C; Akimov M; Slamon DJ; Finn RS
Mol Cancer Ther; 2013 Apr; 12(4):509-19. PubMed ID: 23395886
[TBL] [Abstract][Full Text] [Related]
15. Trastuzumab deruxtecan for HER2+ advanced breast cancer.
Lee J; Park YH
Future Oncol; 2022 Jan; 18(1):7-19. PubMed ID: 34823373
[TBL] [Abstract][Full Text] [Related]
16. DS-8201a, a new HER2-targeting antibody-drug conjugate incorporating a novel DNA topoisomerase I inhibitor, overcomes HER2-positive gastric cancer T-DM1 resistance.
Takegawa N; Nonagase Y; Yonesaka K; Sakai K; Maenishi O; Ogitani Y; Tamura T; Nishio K; Nakagawa K; Tsurutani J
Int J Cancer; 2017 Oct; 141(8):1682-1689. PubMed ID: 28677116
[TBL] [Abstract][Full Text] [Related]
17. Trastuzumab deruxtecan and other HER2-targeting agents for the treatment of HER2-positive gastric cancer.
Ishii T; Shitara K
Expert Rev Anticancer Ther; 2021 Nov; 21(11):1193-1201. PubMed ID: 34543577
[TBL] [Abstract][Full Text] [Related]
18. Association between gain-of-function mutations in PIK3CA and resistance to HER2-targeted agents in HER2-amplified breast cancer cell lines.
Kataoka Y; Mukohara T; Shimada H; Saijo N; Hirai M; Minami H
Ann Oncol; 2010 Feb; 21(2):255-262. PubMed ID: 19633047
[TBL] [Abstract][Full Text] [Related]
19. Novel HER2-Targeting Antibody-Drug Conjugates of Trastuzumab Beyond T-DM1 in Breast Cancer: Trastuzumab Deruxtecan(DS-8201a) and (Vic-)Trastuzumab Duocarmazine (SYD985).
Xu Z; Guo D; Jiang Z; Tong R; Jiang P; Bai L; Chen L; Zhu Y; Guo C; Shi J; Yu D
Eur J Med Chem; 2019 Dec; 183():111682. PubMed ID: 31563805
[TBL] [Abstract][Full Text] [Related]
20. Trastuzumab-deruxtecan: an investigational agent for the treatment of HER2-positive breast cancer.
Bartsch R
Expert Opin Investig Drugs; 2020 Sep; 29(9):901-910. PubMed ID: 32701032
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]